G1 Therapeutics Initiates Three Drug Development Programs in Breast Cancer
Phase 2 trial of trilaciclib in triple-negative breast cancer Phase 1b/2a trial of G1T38 in estrogen receptor-positive breast cancer Oral SERD (G1T48) in IND-enabling studies; Phase 1 trial planned for 4Q17 RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2017 ( …